ARTA
ATRA icon

A.R.T. Advisors’s Atara Biotherapeutics ATRA Stock Holding History

A.R.T. Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,185
Closed -$900K – 121
2019
Q4 		$900K Sell
2,185
-1,348
-38% -$465K 0.04% 605
2019
Q3 		$1.25M Buy
3,533
+1,756
+99% +$655K 0.06% 447
2019
Q2 		$893K Buy
1,777
+1,536
+637% +$1.08M 0.05% 503
2019
Q1 		$239K Buy
+241
New +$224K 0.01% 1027
2017
Q3 		– Sell
-738
Closed -$258K – 1347
2017
Q2 		$258K Buy
+738
New +$284K 0.01% 1066
2016
Q2 		– Sell
-2,558
Closed -$1.22M – 1350
2016
Q1 		$1.22M Buy
2,558
+1,134
+80% +$510K 0.05% 502
2015
Q4 		$940K Buy
+1,424
New +$1.08M 0.04% 588
2015
Q2 		– Sell
-505
Closed -$524K – 1474
2015
Q1 		$524K Buy
+505
New +$334K 0.02% 893

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

A.R.T. Advisors's ATRA Position: Q1 2020 in Review

A.R.T. Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 2,185 shares — an estimated $900K sold.

A.R.T. Advisors first reported a position in ATRA in Q1 2015 and held it in 8 quarters. The position peaked at $1.25M in Q3 2019. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

  • A.R.T. Advisors reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 2,185 Atara Biotherapeutics shares in Q1 2020, an estimated $900K.
  • A.R.T. Advisors first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 8 quarters.
  • A.R.T. Advisors's Atara Biotherapeutics position peaked at $1.25M in Q3 2019.
  • 111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.